Curemark has built a first-in-kind portfolio of products to treat neurological disorders that have previously been underserved by available options.
Our pipeline includes a product candidate in Phase III clinical-stage for Autism, a Phase III-ready product candidate for ADHD, and multiple preclinical programs.
